Xilio Therapeutics Files Initial Ownership Statement
Ticker: XLO · Form: 3 · Filed: Apr 16, 2026
Sentiment: neutral
Topics: insider-filing, ownership, form-3
TL;DR
Xilio Therapeutics filed a Form 3 on 4/15/26. Ownership details to follow.
AI Summary
On April 15, 2026, Xilio Therapeutics, Inc. filed an initial statement of beneficial ownership of securities (Form 3). The filing was made by Cheryl R. Blanchard, who is listed as the reporting person. The company's mailing address is 828 Winter Street, Waltham, MA 02451.
Why It Matters
This filing indicates a change in beneficial ownership for Xilio Therapeutics, Inc., which could signal new investment or strategic shifts within the company.
Risk Assessment
Risk Level: low — A Form 3 filing is a standard initial disclosure and does not inherently represent a change in risk for the company.
Key Numbers
- 2026-04-15 — Period of Report (Date of initial ownership statement)
- 2026-04-16 — Filing Date (Date the Form 3 was officially filed)
Key Players & Entities
- Xilio Therapeutics, Inc. (company) — Issuer
- Cheryl R. Blanchard (person) — Reporting Person
- 0001840233 (company) — Xilio Therapeutics, Inc. CIK
- 0001326530 (person) — Cheryl R. Blanchard CIK
- 001-40925 (company) — File Number
FAQ
What specific securities are being reported in this Form 3?
The provided filing details do not specify the exact securities, only that it is an initial statement of beneficial ownership.
Who is Cheryl R. Blanchard in relation to Xilio Therapeutics, Inc.?
Cheryl R. Blanchard is identified as the Reporting Person for this Form 3 filing.
What is the CIK number for Xilio Therapeutics, Inc.?
The CIK number for Xilio Therapeutics, Inc. is 0001840233.
What is the business address of Xilio Therapeutics, Inc.?
The business address for Xilio Therapeutics, Inc. is 828 Winter Street, Waltham, MA 02451.
What type of company is Xilio Therapeutics, Inc.?
Xilio Therapeutics, Inc. is classified under SIC code 2834, Pharmaceutical Preparations, within the Life Sciences sector.
Filing Details
This Initial Statement of Beneficial Ownership (Form 3) was filed with the SEC on April 16, 2026 by Cheryl R. Blanchard regarding Xilio Therapeutics, Inc. (XLO). Form 3 filings establish the initial ownership position of company insiders when they first assume their role.